Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
about
The role of miR-29b in cancer: regulation, function, and signalingMicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tunePredicting response to epigenetic therapyIDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsSequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesmiR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implicationsToward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in RodentsTargeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.Epigenetics of myelodysplastic syndromes.MicroRNAs expressed in hematopoietic stem/progenitor cells are deregulated in acute myeloid leukemias.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.MicroRNAs in Myeloid Hematological Malignancies.Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancerHypomethylating Agents as a Therapy for AML.Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.miR-9 is a tumor suppressor in pediatric AML with t(8;21).
P2860
Q26851543-FFE97EB3-B3D0-4D6B-851F-D4753F02C479Q27013740-F6E2C834-AD11-4EC8-8878-9A7ADFF57E8FQ27027751-A61E7D7D-FC69-4896-8418-4AFA207B18DBQ27692015-E3ED0E0A-C1E0-4289-A666-E41687ABC0D6Q28071427-083D434F-3FA1-4021-AF33-9D09D6F3D854Q31149399-267E72AA-23A6-4B48-B98B-70C08B5493DFQ34661033-2FCF685A-DC52-46B8-AB6C-7BD501521E2DQ36256357-9D87DF54-2AD4-4EA8-A867-4E4B9213036BQ36542965-F2986D8E-BAD8-4E0A-8CA3-59424469309BQ37394708-4BBE4A5E-4C89-4C3D-87D3-D45D9D54AF18Q37600352-332EBF97-AFF9-47C1-81CE-0AC2EC4E167EQ37644854-70F3E676-48E8-4BC3-A5DE-C51E5BB10DBDQ37679943-C8C7BF02-AA7E-4E4F-A57E-33BF40F212ACQ38163846-EB306A76-9BD9-47B6-959F-E2F69FC584BBQ38252974-236B9176-1A59-4D53-95B9-9658B07888D6Q38476564-BFADA7B9-B7B1-4A08-AA9D-C4AA6A5C4D6AQ38520091-71829068-98F5-4B67-B7A1-7E5322650566Q38572855-84FFBD5F-57CA-40EF-AC60-161B346FD72EQ38599595-69BA06E9-6DC0-4ACB-ABAC-FB10A16121E8Q38898187-64823809-2F8B-480D-B3CB-3B8860FD2C33Q38911864-C4BED093-A353-4B8D-9D0C-443162BB90F1Q39181050-58152D43-9485-442D-854C-A04CF5F62744Q40356364-6EF189F2-D2E6-4DB4-9AF6-31BE09C8DA44Q41856711-E16CFBD2-A5EC-4E97-B3CB-199099571C27Q46839402-D515C555-489D-4D9E-B864-87AC538E09ABQ48336259-F559E885-41D9-4D4E-9471-340137F1E1DD
P2860
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Increased anti-leukemic activi ...... ach in acute myeloid leukemia.
@en
Increased anti-leukemic activi ...... ach in acute myeloid leukemia.
@nl
type
label
Increased anti-leukemic activi ...... ach in acute myeloid leukemia.
@en
Increased anti-leukemic activi ...... ach in acute myeloid leukemia.
@nl
prefLabel
Increased anti-leukemic activi ...... ach in acute myeloid leukemia.
@en
Increased anti-leukemic activi ...... ach in acute myeloid leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Increased anti-leukemic activi ...... ach in acute myeloid leukemia.
@en
P2093
A M Dorrance
A R Walker
D Perrotti
G Marcucci
P2860
P2888
P304
P356
10.1038/LEU.2012.342
P577
2012-11-26T00:00:00Z
P6179
1012607763